ALGS Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Aligos Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerALGS

Market Cap33.6M

Cash RunwayRunway 6-12 months

Next Catalystn/a

Public Research Snapshot

Aligos Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for COVID-19 in better efficacy (Phase 1).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Improving Patient Outcomes	better efficacy	n/a	n/a	Public pipeline row
Pevifoscorvir sodium	chronic hepatitis B virus infection	Small Molecule	n/a	Public pipeline row
ALG-055009	metabolic dysfunction-associated steatohepatitis (MASH)	Small Molecule	n/a	Public pipeline row
COVID-19	n/a	n/a	Phase 1	Public pipeline row
GLP-1	n/a	Peptide	n/a	Public pipeline row
PD-1	n/a	Small Molecule	Preclinical	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
No public trial rows are loaded yet.

Scientific Context

indication | liver and viral diseases Science Driven Utilizing the expertise of our medicinal
indication | liver and viral diseases Science Driven Utilizing the expertise of our medicinal
indication | liver and viral diseases Science Driven Utilizing the expertise of our medicinal
indication | liver and viral diseases Science Driven Utilizing the expertise of our medicinal
modality | small molecule

Want the full ALGS research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.